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Introduction: 
Macrophages are the building blocks of intimal atherosclerotic lesions where they scavenge 
and accumulate modified lipoproteins, profoundly impacting lesion development and 
progression through their roles in lipid metabolism and as major sensors and effectors of the 
innate immune system 1. Lesional macrophages originate from circulating monocytes, 
although more recent work indicates that a subpopulation may also derive from 
dedifferentiated vascular smooth muscle cells 2, 3. Resident macrophages are found in the heart 
at steady state and along with newly recruited monocyte-derived macrophages accumulate 
after myocardial infarction 4, 5. Macrophage turnover in atherosclerotic lesions and ischemic 
myocardium is under the control of several biological processes, including monocyte 
recruitment, macrophage proliferation and apoptosis as well as macrophage egress 6, 7. 
Moreover, local microenvironment whether in health or disease profoundly impacts 
macrophage phenotype 8, 9 and consequently, both metabolic and immune-related responses 10. 
Here, I summarize recent work published in ATVB on the roles of monocytes/macrophages in 
cardiovascular diseases (CVD) and review it in light of the most recent advances in this 
research area. 
 
Monocytes, macrophages and the pathogenesis of atherosclerosis: 
Monocyte activation/recruitment and macrophage trapping within the lesions: monocytes 
play central roles in atherogenesis and are rapidly attracted to sites of disturbed flow 
characterized by low-grade inflammation 11. The use of advanced 10-fluorochrome, 13-
prameter flow cytometry method recently allowed detailed characterization of the dynamics 
of immune cell accumulation during flow-induced (partial carotid artery ligation) 
atherogenesis in Apoe-/- mice. The study showed that monocytes/macrophages constitute the 
most abundant cell population in the intima where they rapidly accumulate as early as 4 days 
after induction of flow disturbance, peak at day 7 and remain relatively stable between day 14 
and day 28 12. Disturbed flow promotes endothelial cell activation in part through repression of 
major anti-adhesive and anti-thrombotic transcription factors, Klf2 and Klf4 13-16. In fact, a 
single microRNA, mir-92a, coregulates Klf2 and Klf4 expression and contributes to the 
heterogeneity of endothelial cell phenotype in atheroprone versus atheroresistant arterial sites 
17-19. Hypercholesterlemia combined with low shear stress markedly upregulates endothelial 
expression of mir-92a in a Stat3-dependent manner. Blockade of mir-92a restores Klf2 and 
Klf4 expression, reduces endothelial inflammation and monocyte infiltration, thereby limiting 
atherosclerosis 19. Disturbed flow as well as other pro-atherogenic factors also downregulate 
the endothelial expression of negative guidance cues, particularly Netrin-1 and 
Semaphorin3A, while upregulating EphrinB2, and facilitate chemokine-directed migration of 
monocytes and their infiltration within the intima 20. Interestingly, Klf2, Klf4 and Netrin-1 are 
also expressed in monocytes/macrophages and regulate their phenotype/function during 
atherogenesis 21-24. Klf2 and Klf4 limit monocyte/macrophage activation in part through the 
regulation of selective microRNAs (mir-124a, mir-150) 25 and promote an alternatively 
activated M2 phenotype associated with reduced susceptibility to atherosclerosis 22, 23. However, 
Netrin-1 expression in macrophages, which is highly upregulated by hypoxia-inducible 
transcription factor (HIF)-1a 26, promotes the progression of atherosclerosis through its 
profound impact on macrophage migration, limiting their emigration and retaining them 
within the developing atherosclerotic lesions 24. The same group recently extended this 
concept to another guidance molecule, Semaphorin3E, and showed that it’s upregulated in M1 
macrophages where it blocks actin polymerization and migration in response to chemokine 
stimulation, thereby contributing to macrophage retention within the lesions 27. Of note, low 
expression of Netrin-1 and Unc5b in macrophages and smooth muscle cells of human 
atherosclerotic lesions was associated with signs of plaque instability 28. 
	 3	
 
Recent studies have re-emphasized the subtle but crucial roles of post-translational 
glycosylation of endothelial cell or leukocyte ligands and receptors involved in cell-cell 
interactions, 29. Disturbed flow and pro-inflammatory mediators increase hypoglycosylated, 
high-mannose and hybrid N-glycans on the endothelial cell surface at sites of early lesion 
development, which leads to increased monocyte adhesion 30. On the other hand, 
sialyltransferase IV activity, which catalyzes the formation of a sialylated sLex, appears to 
promote monocyte recruitment into inflamed arteries and promotes atherogenesis through its 
essential role in the generation of a functional Ccr5 receptor 31, suggesting that selective 
targeting of these post-translational events may constitute an interesting therapeutic option. In 
addition to Ccr5, signaling events through Ccr2 and Cx3cr1 play non-redundant roles in 
atherosclerosis 32-34. Interestingly, more recent studies on Cx3cr1 suggest upregulation of this 
chemokine receptor on platelets in response to hyperlipidemia, which promotes platelet-
monocyte complex formation and supports monocyte arrest on inflamed vascular cells, 
thereby identifying a new mechanism leading to platelet accumulation and monocyte 
recruitment at sites of arterial injury 35. Pharmacological targeting of Cx3cr1 through the 
administration of an amino terminus-modified Cx3cr1 ligand endowed with antagonist 
activity substantially limits monocyte trafficking into lesions and halts the development and 
progression of atherosclerosis 34. 
  
Monocyte differentiation into macrophages is a pivotal process in atherogenesis and is 
regulated through a coordinated developmental program dependent on the balance between 
several transcription factors, including MafB, c-Maf, Icsbp/Irf8, Klf4, Pu.1 and the 
macrophage-specifying zinc finger transcription factors Egr-1 and Egr-2 36, 37. A recent study 
published in ATVB proposed caveolin-1, the structure protein of caveolae, as a critical 
regulator of monocyte differentiation through Erk phosphorylation, leading to increased Egr-1 
nuclear translocation and transcriptional activity 38. A broader view of the molecular 
mechanisms controlling monocyte activation and priming towards the macrophage phenotype 
is emerging. Recent studies identified distinct dynamic epigenetic, transcriptional and 
metabolic programs controlling monocyte differentiation towards either tolerant or activated 
‘trained’ phenotypes 39, 40. This is highly consistent with a more focused work showing that 
brief exposure of monocytes to oxLDL increases trimethylation of lysine 4 at histone 3 in 
promoter regions of several pro-inflammatory mediators and scavenger receptors (CD36, SR-
A) leading to foam cell formation and long-term proinflammatory cytokine production 41 via 
epigenetic reprogramming. Such sustained changes in monocyte/macrophage phenotype may 
further promote and sustain immune cell activation. For example, CD36-dependent activation 
of monocytes generates an intracellular transduction pathway leading to Rac and Jnk2 
activation downstream of the guanine nucleotide exchange factor Vav1, which contributes to 
enhanced monocyte adhesiveness to inflamed endothelium 42. This is reminiscent of the role of 
CD36 in the trapping of macrophages within atherosclerotic lesions previously shown to be 
dependent on alteration of cytoskeletal dynamics through sustained activation of Fak and 
reduced migration 43. Interestingly, AT1 receptor activation may upregulate CD36 expression 
on macrophages, sustain Fak activity and contribute to macrophage trapping in the intima, 
leading to heightened plaque inflammation and increased susceptibility to rupture 44. In this 
regard, a more recent study indicates that ACE, the enzyme that converts angiotensin (Ang)I 
into AngII, is highly expressed in lesional macrophages where it contributes to lesion 
development 45, although the effect was modest and limited to the aortic arch. Superimposed 
metabolic stress factors, like high LDL and D-glucose concentrations may further prime 
monocytes and enhance their chemotaxis through increased S-glutathionylation and 
remodeling of actin downstream of NADPH oxidase 4. In contrast, regulators of lipid 
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metabolism such as Apoe may suppress atherosclerosis through reduced lipid accumulation in 
monocytes and downregulation of monocyte activation, independently of their lipid-lowering 
properties 46. 
 
More on foam cell formation and macrophage activation/deactivation: Monocyte 
differentiation into macrophages is associated with upregulation of phagocytic activity 
leading to lipid accumulation and formation of typical foam cells. Recent findings suggest 
that cardiovascular risk factors other than elevated plasma cholesterol levels may significantly 
modulate macrophage foam cell formation. For example, the endogenous nucleoside 
adenosine, which is released extracellularly under stress conditions, profoundly impacts foam 
cell formation through G protein coupled receptor A(2A)-dependent regulation of reverse 
cholesterol transport (reviewed in 47). Increased expression of xanthine oxidoreductase (XOR), 
a key enzyme in the uric acid production pathway, is upregulated in many cardiovascular 
disease settings and localizes to macrophages. Recent data indicate that overexpression of 
XOR promotes foam cell formation through upregulation of VLDL and scavenger receptors 
and downregulation of ATP-binding cassette transporters (ABCA1 and ABCG1) along with 
induction of a pro-inflammatory phenotype, all effects being prevented by treatment with 
allopurinol, which markedly limits lipid accumulation and lesion calcification in aortas of 
Apoe-/- mice 48. Hypertriglyceridemia is an important cardiovascular risk factor and 
triglyceride-mediated pathways are causally related to coronary disease 49. Bojic et al show 
that VLDL treatment of macrophages leads to triglyceride accumulation and induces AP1-
dependent pro-inflammatory cytokine production, downstream of Erk1/2 and Akt/Foxo1. 
PPARd agonists attenuated VLDL-stimulated triglycerides accumulation through reduction of 
lipoprotein lipase (LPL) activity, increased fatty acid uptake and enhanced b-oxidation, and 
inhibited VLDL-dependent inflammation through normalization of Erk and Akt/Foxo1 
signaling 50, which led to an M2 macrophage phenotype and limited the progression of pre-
established atherosclerosis in mice 51. Angiopoietin-like 4 (ANGPTL4) is an endogenous 
inhibitor of LPL. Nonsynonymous variants in ANGPTL4 were initially associated with 
reduced triglycerides levels and increased HDL 52. However, subsequent larger studies failed 
to establish a correlation between ANPTL4 variants or plasma levels and serum triglycerides, 
although plasma ANGPTL4 negatively associated with HDL-cholesterol 53. Therefore, an 
uncertainty remained regarding the potential impact of such variants on cardiovascular 
disease. A recent work in ATVB clearly shows that transgenic overexpression of Angptl4 
suppresses foam cell formation and significantly reduces atherosclerosis in mice despite no 
alteration of plasma cholesterol or triglycerides levels 54, supporting a protective effect of 
Angptl4 and a potential impact of ANGPTL4 variants on CVD beyond any role on serum 
lipid levels. 
Macrophage foam cell formation and inflammation are prominent features of atherosclerotic 
lesions. However, recent work indicates that cholesterol accumulation does not invariably 
lead to inflammation. In fact, analysis of elicited peritoneal macrophages in WT and Ldlr-/- 
mice fed either a chow or a high fat high cholesterol diet revealed massive reprogramming of 
the lipidome in response to both diet and genotype, and an unexpected deactivation of the 
inflammatory response in the macrophage foam cells 55. The underlying mechanisms involved 
regulated accumulation of desmosterol in foamy macrophages, which was responsible for 
downstream activation of LXR and inhibition of SREBP target genes, leading to selective 
reprogramming of fatty acid metabolism and the establishment of an anti-inflammatory 
homeostatic response 55. In line with these observations, Suzuki M et al were unable to detect 
any evidence for increased expression of inflammatory proteins after in vitro loading of 
peritoneal macrophages with acetyl-LDL, and demonstrated that sterol loading blunted the 
macrophage response to LPS without altering the overall pattern of LPS-induced gene 
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expression 56. However, their use of transcriptomics and proteomics to investigate molecular 
changes induced in cholesterol-loaded macrophages revealed a differential activation, mainly 
through post-transcriptional mechanisms, of 3 functional modules corresponding to lipid 
metabolism, lysosomal biology and, unexpectedly, complement activation, both the classic 
and the alternative pathways 56. Thus, despite no direct induction of an inflammatory program 
in foam cell macrophages, complement regulation by sterol loading may have important 
consequences on the immune response and the development of atherosclerosis 57. It should 
also be noted that enrichment of monocyte/macrophages with unesterified cholesterol 
generates biologically active PS-expressing microvesicles that may carry not only a 
thrombotic potential but also danger signals like peroxides, induced through activation of 
mitochondrial complex II and exported on the microvesicles, and capable of disseminating 
maladaptive immune responses through activation of pattern recognition receptors 58. The true 
clinical in vivo relevance of these pathways is still unexplored. 
 
Innate Inflammatory signaling pathways: An intriguing role for TLR7/9 signaling in foam cell 
formation has been reported recently 59 beyond its role in macrophage activation. However, the 
molecular mechanisms behind this observation remain to be elucidated. Other work has 
expanded on the role of inflammatory signaling in macrophages as a major driver of 
atherogenesis. Some studies proposed a role for NOD2-mediated activation of macrophages 
within the lesions, leading to p38-dependent activation of COX-2 through upregulation of 
pro-inflammatory cytokines IL1b and TNFa, and culminating in increased eicosanoid 
production (mostly prostaglandin E2) 60. Macrophages can also be primed for increased 
eicosanoid (including PGE2) secretion following LXR-mediated induction of 
lysophosphatidylcholine acyltransferase 3 61. In this regard, suppression of myeloid-derived, 
but not vascular cell-derived, PGE2 substantially reduces atherosclerosis 62. Other studies 
confirmed a pivotal role for NF-kB pathway, and more particularly myeloid-specific IkB 
kinase activity, in sustaining macrophage inflammation and promoting lesion development 63. 
A number of interesting inflammatory pathways that converge on NF-kB activation have been 
reported. Sphingomyelin generation in macrophages through sphyngomyelin synthase 1 
promotes atherosclerosis through accentuation of TLR4-dependent NF-kB signaling 64. 
TWEAK-mediated activation of monocytes/macrophages through fibroblast growth factor 
inducible 14 increases the release of the pro-inflammatory and pro-atherogenic HMGB1 65, 66, 
and upregulation of resistin-like molecule (RELM)b on foam cell macrophages by saturated 
fatty acids potentiates the classical NF-kB pathway and accelerates lesion development 67. An 
additional intriguing mechanism of macrophage activation involves interference with 
extracellular matrix remodeling through activation of heparanase activity, which cleaves 
heparin sulfate side chains. Blich et al nicely showed that heparanase potently activated 
macrophages to upregulate TNFa, IL-1, MCP-1 and MMP-9, likely through TLR2/4, PI3K, 
MAPK, and NF-kB signaling pathway 68. How heparanase activates TLRs is till unknown but 
may involve conformational changes in cell membrane HS proteoglycans, generation of HS-
cleavage products, or other HS-independent function. Of note, vulnerable coronary plaques 
showed increased heparanase activity compared with stable lesions, and elevated plasma 
heparanase levels were found in patients with acute myocardial infarction compared with 
stable patients, highly suggesting a clinically-relevant pathway 68. 
Metabolic disturbances associated with obesity and insulin resistance drive cardiovascular 
complications 69, 70. Free fatty acids (FFA) are elevated in patients with the metabolic syndrome 
and are proposed to promote inflammatory responses through TLR and NF-kB-dependent 
signaling. Recent studies provided additional mechanisms for FFA-dependent regulation of 
the inflammatory response. Saturated FFA palmitate induces the activation of NLRP3-ASC 
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inflammasome leading to increased production of IL-1b (and IL-18) 71, whereas unsaturated 
oleate selectively induces inflammasome-independent IL-1a production through activation of 
mitochondrial uncoupling 72. Recent work published in ATVB indicates that stearic acid, a 
major saturated FFA in atherosclerotic lesions, activates TLR2/4-independent inflammation in 
macrophages, with induction ER stress and macrophage apoptosis 73, suggesting potentially 
important consequences with regard to lesion progression, given the well-documented roles of 
ER stress, macrophage apoptosis and defective efferocytosis in promoting plaque 
inflammation and necrotic core formation 74-76. Conversely, n-3 fatty acids are endowed with 
anti-inflammatory properties. For example, eicosapentaenoic acid has recently been shown to 
limit the induction of macrophage endothelial lipase in response to a variety of stimuli, 
including LPS, palmitic acid or PPARg agonists. The effect was associated with reduced 
production of pro-inflammatory mediators but upregulation of anti-inflammatory IL-10 77. 
Moreover, administration of omega-3 fatty acids to Ldlr-/- or Apoe-/- mice led to significant 
reduction of Ly6Chi monocytosis and monocyte recruitment into developing lesions, 
independently from effects on plasma cholesterol 78. More generally, omega-3 fatty acids were 
recently shown to uncouple NF-kB binding and histone acetylation at enhancers and 
promoters from subsequent steps required for induction of inflammatory genes, particularly 
histone methylation and eRNA production 79. 
Intraplaque hemorrhage (IPH) is an important risk factor for plaque progression and 
vulnerability where erythrophagocytosis by macrophages appears to play a determinant role 80, 
81. However, the mechanisms behind this increased susceptibility to atherosclerosis are poorly 
understood. Two studies published in ATVB suggest a critical role for hepcidin, a key 
regulator of iron homeostasis, in driving foam cell formation (in part through modulation of 
ABCA1 and ABCG1 expression), oxidative stress and production of pro-inflammatory 
cytokines by macrophages, particularly in association with erythrophagocytosis 82, 83, 
highlighting a mechanistic link between iron retention in macrophages, inflammatory 
activation and lesion progression.  
 
Anti-inflammatory signaling pathways: IPH has also been shown to generate a distinct 
adaptive macrophage state in lesions 84 dependent on a key transcription factor ATF1 induced 
by heme 85, and the associated induction of LXR and HO-1 target genes 86, 87. Heme-induced 
HO-1 in macrophages requires NRF-2 88, recently shown to prevent oxidative stress in these 
cells, leading to limitation of plaque inflammation and progression 89. Moreover, activation of 
5’-AMP-activated protein kinase (AMPK) is instrumental in heme-induced ATF1 and 
downstream suppression of macrophage oxidative stress and protection from foam cell 
formation 87. This may provide potential explanation for the vasculoprotective effects of the 
AMPK activator metformin and its unique ability to reduce the macrovascular complications 
of diabetes 90 amongst many other anti-diabetic treatments. Remarkably, AMPK activation by 
metformin was recently shown to suppress trained immunity in macrophages through 
inhibition of mTOR 40, revealing a potentially broader role for this pathway in the regulation of 
macrophage immune activation versus tolerance.  
 
Macrophage polarization is proposed to play determinant roles in cardiovascular diseases and 
the topic has been the subject of many recent reviews in ATVB 91-98. Additional original work 
further highlighted the mechanisms and the impact of macrophage polarization on 
atherosclerosis. For example, deficiency of Klf4 in macrophages limits M2 and promotes a 
pro-atherogenic M1 phenotype 23, whereas control of oxidative stress by thioredoxin is 
reported to favor the development of an athero-protective M2 phenotype 99. M2 polarization is 
dependent on fatty acid oxidation. Interestingly, cell-intrinsic lysosomal lipolysis by 
lysosomal acid lipase (LAL) appears to be essential for the induction of a coordinated 
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program leading to alternative activation of macrophages 100. Autophagy has previously been 
shown to regulate cholesterol efflux in macrophages through targeting of LAL to lipid 
droplets with subsequent hydrolysis of cholesteryl esters and generation of free cholesterol for 
ABCA1-dependent efflux 101-103. However, no evidence is available yet to directly implicate 
autophagy in LAL-dependent induction of an M2 phenotype, although it plays pivotal roles in 
macrophage homeostasis, limiting oxidative stress, inflammasome activation and promoting 
efferocytosis and anti-atherogenic pathways 104, 105. Additional studies expanded on the role of 
TIMP3 in macrophage biology based on previous work that highlighted the invasive potential 
of TIMP3(-)MMP14(+) foam cell macrophages 106. The new results show that TIMP3 is 
upregulated by classic but downregulated by alternative macrophage activation 107, and that 
overexpression of TIMP3 in macrophages leads to reduction of oxidative stress, decreased 
inflammation, and a stable plaque phenotype 108. The exact mechanisms behind this 
observation remain to be elucidated. Additional work on the consequences of PPARg 
activation in macrophages revealed selective activation of 11b-hydroxysteroid dehydrogenase 
type 1 (11b-HSD1) in M2 versus M1 macrophages 109. Upregulation of 11b-HSD1 would 
increase conversion of cortisone into active cortisol. The authors suggested that this might 
promote improved resolution of the inflammatory response. However, direct inhibition of 
11b-HSD1 or its deletion in bone marrow-derived cells do not promote but rather limit 
atherogenesis through reduction of inflammatory macrophage phenotype and improved 
cholesterol ester export 110. Thus, additional work is needed to better clarify the relevance of 
PPARg-induced 11b-HSD1 in M2 macrophages. Finally, a new anti-inflammatory mechanism 
for apoA-I mimetic peptide 4F was reported, involving disruption of lipid rafts, reduced 
recycling of TLR4 after LPS stimulation and inhibition of NF-kB-dependent pro-
inflammatory gene expression 111. 
 
Macrophages in aortic aneurysm 
Abdominal aortic aneurysm is characterized by extensive remodeling of the arterial wall, 
leading to wall thinning, weakening, dilatation and rupture 112. Despite extensive studies 
implicating the inflammatory response in AAA 113, little is known about the role of 
monocyte/macrophages in disease pathogenesis. Monocyte depletion reduces AAA formation 
in mice 114. However, the distinct contributions of the various monocyte/macrophage subsets to 
AAA are still relatively unexplored. A few recent studies published in ATVB started to 
address some of these issues. Two studies highlighted the important role of chemokine-
dependent monocyte recruitment through Ccr2 or Cxcl4-Ccl5 in the development of AAA 115, 116 
using AngII-dependent 115, 116 or elastase-induced models 115. The studies suggested new 
therapeutic medical strategies for this disease using peptide-mediated inhibition of Cxcl4-
Ccl5 interactions 115 or treatment with everolimus to inhibit AngII-induced Ifng production and 
Ifng-induced Ccr2 expression on monocytes 116. A note of caution however should be added for 
everolimus, recently shown to trigger cytokine release by macrophages through mTOR 
inhibition and activation of p38 Mapk 117. Additional studies addressed the impact of 
modulation of macrophage functions on the development of AAA. Haploinsufficiency of 
Notch1 in bone marrow-derived cells reduced the incidence of AngII-induced AAA in Apoe-/- 
mice, which was associated with reduced aortic influx and accumulation of macrophages, 
reduced macrophage migration and proliferation in vitro and a switch towards an M2 
phenotype 118. The results extend previous work that implicated Notch1 signaling in the 
pathogenesis of aortic valve calcification/bicuspidy and thoracic aortic aneurysm. Another 
study addressed the role of macrophage-derived Angptl2 in the pathogenesis of AAA 119. 
Angptl2 expression is known to be induced in several inflammatory settings, including 
obesity-related insulin resistance 120, and is particularly associated with smoking, the dominant 
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risk factor for AAA 121. Deletion of Angptl2 in bone marrow-derived cells led to protection 
from CaCl2-induced AAA, which was associated with reduced macrophage activation and 
blunted MMP9 production 119, suggesting a major impact on vascular inflammation, probably 
through inhibition of IkB degradation 120 and matrix remodeling. The relevance of macrophage 
phenotype to AAA pathogenesis in humans is exemplified in one study that used advanced 
laser capture microdissection to characterize macrophage subsets in aortic tissue, and showed 
that different macrophage subsets localized to distinct regions in the aneurysmal tissue, with 
preferential localization of an inflammatory CD68(+)mannose receptor(-) subset to adventitia, 
whereas the intraluminal thrombus predominantly harbored an anti-inflammatory 
CD68(+)MR(+) macrophages 122. Interestingly, the inflammatory subset was enriched in 
peroxiredoxin-1, suggesting a predominant contribution to oxidative stress in AAA, and a 
potential role in AAA development and progression, given that serum peroxiredoxin-1 levels 
positively correlate with AAA size and growth rate 123.   
 
Macrophages in heart diseases 
The last few years witnessed important progress in our understanding of the immune response 
to ischemic injury, and more particularly the role played by the various subsets of 
monocytes/macrophages in this process 124. Selective macrophage subsets (mainly of yolk-sac 
origin) populate the heart at steady state, are capable of self-renewal and probably play a role 
in immune surveillance 4, 5. Following injury, the contribution of monocytes and monocyte-
derived macrophages become predominant with distinct pathogenic and/or protective roles for 
Ly6Chi and Ly6Clo monocyte subsets 76, 125, respectively, but still poorly defined roles for the 
newly accumulated macrophage subsets in coordinating inflammation versus reparative 
processes 4. A few recent studies published in ATVB examined the regulation and function of 
macrophages in response to heart injury. Deletion of the chemokine decoy receptor D6, which 
binds and selectively inactivates inflammatory CC-chemokines, led to larger infarcts and 
increased incidence of cardiac rupture in mice subjected to coronary artery ligation 126. The 
results were attributed to heightened Ccl2/3 activity, increased accumulation of neutrophils 
and Ly6Chi monocytes in the ischemic heart, along with upregulation of inflammatory 
signaling and Mmp2/9 activities. The whole phenotype was reversed after reconstitution of 
D6-/- animals with Ccr2-deficient bone marrow, clearly implicating leukocyte-selective Ccr2 
signaling in the myocardial response to ischemic injury. Deletion of Irak-M, a functional 
decoy that lacks endogenous kinase activity and inhibit Tlr and I1-1 responses, resulted in 
enhanced post-ischemic inflammation and adverse myocardial remodeling 127. The effects were 
attributed to direct regulation of MMPs and inflammatory signaling in cardiac fibroblast, 
which led to secondary accumulation of Ly6Chi monocytes. Two studies addressed the role of 
macrophage phenotype in mediating the cardiac fibrogenic effects of AngII 128, 129. Both studies 
concluded to an important role of M2 induction in this process, which stimulated cardiac 
fibroblasts to differentiate into a-smooth muscle actin- and collagen I-positive myofibroblasts. 
One study identified a requirement for serum glucocorticoid kinase 1 in promoting optimal 
Stat3 phosphorylation downstream of AngII, favoring the differentiation towards M2. In the 
other study, the authors unraveled an interaction between CD4+ T cells and macrophages that 
coordinated the induction of the M2 phenotype. Deletion of Il-12p35 in macrophages favored 
T cell differentiation towards Th2, which in turn, was required for an optimal switch towards 
the M2 phenotype. 
 
Macrophages as diagnostic, prognostic or therapeutic targets in CVD 
Macrophages as imaging targets: Non-invasive in vivo visualization of inflammatory 
processes within vascular lesions or injured tissues may allow better classification of patients 
at high risk of cardiovascular events. Non-conjugated ultrasmall superparamagnetic iron 
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oxide (USPIO) particles allow the detection of phagocytic cell activity and have shown 
promise in identification of inflammatory vascular lesions. In a recent study, Hasan et al have 
extended the methodology to the detection of inflammatory cerebral aneurysms in humans 
using ferumoxytol-enhanced magnetic resonance imaging (MRI) and showed selective uptake 
by CD68(+) macrophages 130. Three other groups developed MRI protocols and used 
functionalized USPIO or micron-size range iron oxide (MPIO) particles to target cells 
expressing vascular cell adhesion molecule (Vcam)-1 within atherosclerotic lesions of Apoe-/-  
mice 131-133. Significant plaque enhancement was detected with the functionalized compared with 
the uncoupled particles. Moreover, histological analyses revealed that iron localized not only 
to endothelial cells but accumulated mostly in cap and necrotic core macrophages when using 
USPIO to target Vcam-1, suggesting a high potential for this technique to identify vulnerable 
lesions. The Choudhury group in fact produced dual-ligand MPIO targeted to both Vcam-1 
and P-selectin and imaged mice using a 9.4-T magnet 133. The investigators showed selective 
targeting of atherosclerotic lesions using the functionalized MPIO and histological analysis 
revealed selective localization of MPIO to endothelium overlying atherosclerotic lesions, with 
no MPIO detected within lesions, indicating no or minimal uptake by macrophages. 
Nevertheless, dual labeling with Vcam-1 and P-selectin directly correlated with the extent of 
macrophage accumulation within the lesions over a time course of 30 weeks (with a peak of 
macrophage accumulation at 20 weeks of age), suggesting that imaging of activated 
endothelium can be used as a good surrogate of lesional macrophage content. The results 
nicely support the concept of macrophage accumulation being highly dependent on 
continuous monocyte recruitment but do not really fit with the idea that macrophage 
proliferation within the lesions plays a pivotal role in lesion progression 7. To directly image 
macrophages within lesions, Biessen’s group designed and validated a strategy to detect cells 
expressing SR-AI 134, 135, a scavenger receptor abundantly expressed by macrophages. Injection 
of USPIO conjugated with a specific peptidic SR-AI ligand into humanized Ldlr-/- mice led to 
a 3-fold improvement in contrast-to noise ratio of atherosclerotic lesions in comparison with 
mice injected with nontargeted USPIO or mice with leukocyte SR-AI deficiency, suggesting 
an interesting strategy to target phagocytic activity in atherosclerotic lesions. In another work 
by Burtea et al, the authors used USPIO particles conjugated with a linear hexapeptide R826 
to target phosphatidylserine, a biomarker of apoptosis 132. Remarkably, injection into Apoe-/- 
produced specific negative enhancement of plaques rich in macrophages and neutral fat after 
visualization using a 4.7-T Burker MRI, again suggesting a potentially useful tool to track 
vulnerable plaques. 
Additional imaging modalities are being tested, including intravascular optical coherence 
tomography using near-infrared light which provides images within 10- to 20-µm axial 
resolution, and recently shown to discriminate macrophage rich areas within Apoe-/- lesions 136. 
Others have used multispectral and multimodal intravital fluorescence molecular imaging to 
detect and quantify the inflammatory process elicited in response to (FeCl3-induced) deep 
vein thrombosis (DVT) in mice and assess the impact of DVT on subsequent DVT resolution 
137. Their work demonstrates the feasibility of integrated multitarget imaging modality using 
macrophage and MMP activity fluorescence imaging agents in this setting to detect and 
quantify the intensity of thrombus inflammation, and predicts the magnitude of subsequent 
DVT resolution. 
 
Monocytes/macrophages as prognostic targets: There’s growing interest in the study of the 
relationship between murine and human monocyte/macrophage subsets 138, 139, and more 
generally whether knowledge accumulated from animal studies can be extrapolated to the 
human setting 140, 141. Regarding monocytes and CVD, it is interesting to note that the few human 
translational studies conducted to date have so far provided support to the experimental data. 
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Circulating levels of classical CD14++CD16- and intermediate CD14++CD16+ monocytes, but not 
CD14+CD16++ nonclassical monocytes, have been independently associated with 
cardiovascular events (death, MI, stroke) at follow-up in 2 relatively large cohorts of coronary 
patients 142 or individuals with no prevalent CVD 143. In further support of the use of 
monocytes/macrophages as biomarkers of CVD in humans, Reiner et al convincingly reported 
an independent association between circulating levels of soluble CD14 and incident 
cardiovascular events or all-cause mortality in a cohort of >5000 European-American and 
black older adults, and identified new genetic determinants of sCD14 144. However, there was 
no evidence of association between CD14 genotype and CVD risk, suggesting no causal 
relationship. 
 
Monocytes/macrophages as therapeutic targets: Preliminary data suggest that inhibition of 
PAI-I/LRP1 interactions using a small molecule inhibitor impairs macrophage migration and 
limits macrophage accumulation in a model of renal injury 145. The relevance of the finding to 
atherosclerosis is still uncertain as macrophage LRP1 regulates efferocytosis 146 and plays a 
major homeostatic role in vessels, preserving vascular integrity 147, 148. Two initially lipid-
targeting strategies have now been shown to limit monocyte/macrophage-related 
inflammatory processes, independently from their effects on lipid metabolism. Treatment with 
omega-3 fatty acids is shown to limit atherosclerosis through reduction of Ly6Chi monocyte 
recruitment 78 and nicotinic acid (NA) may activate GPR109A to limit NF-kB-dependent 
monocyte activation, chemotaxis and adhesion on inflamed endothelium in vitro 149. This is of 
high relevance to atherosclerosis, as GPR109A is expressed in lesional macrophages 
(although it may be downregulated in foam cells) and NA has been shown recently to limit 
lesion progression in a GPR109A-dependent manner using Ldlr-/- mice 150. In further support of 
the anti-inflammatory properties of NA/GPR109A axis, GPR109A signaling promotes anti-
inflammatory properties in colonic macrophages and dendritic cells (high production of IL-
10) in vivo, and favors the differentiation of Tr1-like IL-10-producing T cells endowed with 
homeostatic properties 151. Thus, targeting GPR109A signaling in monocytes, macrophages 
and dendritic cells may be useful in limiting maladaptive innate and acquired immune 
responses in CVD.  
Macrophages in AAA can readily be imaged with the modified glucose 18 fluoro-
deoxyglucose by positron emission tomography imaging 152, which is associated with enhanced 
expression of glucose transporters 1 and 3 153. Interestingly, administration of glycolysis 
inhibitor 2-deoxyglucose significantly attenuated AAA formation in 2 mouse models of the 
disease 153, which was associated with reduced monocyte/macrophage inflammation, MMP 
production and survival/proliferation. This agrees in general with the role of glycolysis in 
supporting trained immunity in macrophages 40 and dendritic cells 154 and could be extended to 
adaptive effector immune cells 155. Thus, glycolysis inhibition might prove to be a viable 
therapeutic option to limit pathogenic immune responses in CVD. 
Diagnostic and imaging modalities are being combined with therapeutic agents leading to the 
development of a new research area employing theranostics. A few examples have recently 
been published in ATVB. Maiseyeu et al showed that gadolinium nanoparticles conjugated 
with a neutralizing antibody against myeloid-related protein (Mrp)-8/14 (a secreted protein 
previously shown to promote leukocyte recruitment) limit Mrp-8/14-dependent inflammatory 
activation of bone marrow-derived macrophages in vitro and selectively image inflammatory 
cells in lesions of Apoe-/- mice 156, suggesting a potential theranostic approach for 
atherosclerosis. Others have developed photodynamic therapy to image and kill activated and 
detrimental macrophages within atherosclerotic lesions 157, using a combination of 
photosensitizers and light illumination. In particular, the authors developed a cathepsin B-
activatable theranostic agent, which becomes fluorescent and generates singlet oxygen on 
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protease conversion followed by light therapy. They showed selective imaging of 
macrophage-dependent cathepsin B activity in lesions of Apoe-/- mice, followed by significant 
reduction of macrophage content after application of light therapy, mostly due to macrophage 
apoptosis 157. Future work should define the utility and potential undesirable effects of this 
attractive ‘see-and-treat’ approach. Induction of massive macrophage apoptosis in advanced 
lesions might promote necrotic core formation in the absence of very effective efferocytosis 
pathways.  
 
Conclusion 
Inflammatory processes are central to the pathogenesis and complications of CVD. Yet, no 
anti-inflammatory strategy has been approved for the treatment of patients with CVD, and a 
few have even failed 158, 159, although the inefficacy of non-selective sPLA2 inhibitors could 
have been predicted from both animal 76 and human mendelian randomization studies 160. This 
highlights the urgent need for a better understanding of the cellular and molecular 
determinants of the inflammatory processes related to CVD and the assessment of their 
clinical relevance. The last few years have witnessed an immense advance in the 
characterization of the origins and distinct functions of monocyte/macrophage subsets as well 
as their differential roles in health and disease, and investigators have proposed ingenious 
strategies to track these cells and influence their behavior in vivo. The day is getting closer 
when this novel understanding will be translated into selective and effective diagnostic and 
therapeutic approaches for the benefit of patients. 		 	
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